Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
Upturn AI SWOT - About
QuantumSi Inc (QSI)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
08/14/2025: QSI (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $2.67
1 Year Target Price $2.67
| 1 | Strong Buy |
| 1 | Buy |
| 1 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -67.8% | Avg. Invested days 23 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 08/14/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 226.79M USD | Price to earnings Ratio - | 1Y Target Price 2.67 |
Price to earnings Ratio - | 1Y Target Price 2.67 | ||
Volume (30-day avg) 3 | Beta 2.89 | 52 Weeks Range 0.61 - 5.77 | Updated Date 08/15/2025 |
52 Weeks Range 0.61 - 5.77 | Updated Date 08/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.67 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date 2025-08-05 | When - | Estimate -0.14 | Actual -0.16 |
Profitability
Profit Margin - | Operating Margin (TTM) -4527.58% |
Management Effectiveness
Return on Assets (TTM) -27.01% | Return on Equity (TTM) -46.87% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 23725621 | Price to Sales(TTM) 66.47 |
Enterprise Value 23725621 | Price to Sales(TTM) 66.47 | ||
Enterprise Value to Revenue 6.95 | Enterprise Value to EBITDA 0.63 | Shares Outstanding 182558000 | Shares Floating 165746369 |
Shares Outstanding 182558000 | Shares Floating 165746369 | ||
Percent Insiders 12.49 | Percent Institutions 31.18 |
Upturn AI SWOT
QuantumSi Inc
Company Overview
History and Background
QuantumSi Incorporated was founded in 2013. It is focused on developing next-generation protein sequencing technology. The company went public via a SPAC merger in 2021.
Core Business Areas
- Protein Sequencing: QuantumSi develops and commercializes a single-molecule protein sequencing platform called Platinum. Its goal is to transform proteomics and drug discovery.
Leadership and Structure
Dr. Jonathan Rothberg is the founder and chairman. The CEO is currently TBD. The company has a typical organizational structure with departments for research, development, marketing, and sales.
Top Products and Market Share
Key Offerings
- Platinum: Platinum is QuantumSi's flagship protein sequencing platform. It's designed to analyze single protein molecules. There is limited public data on current revenue or user numbers. Key competitors include Pacific Biosciences (PACB) and other proteomics companies using mass spectrometry and other technologies. Market share is estimated to be low as the product is new in the market. Competitors includes SomaLogic and Olink.
Market Dynamics
Industry Overview
The proteomics market is experiencing growth, driven by increasing demand for personalized medicine and drug discovery. Advancements in sequencing technologies are fueling this expansion.
Positioning
QuantumSi aims to disrupt the proteomics market with its single-molecule sequencing technology. Their competitive advantage lies in potential advantages in sensitivity and resolution compared to traditional methods.
Total Addressable Market (TAM)
The proteomics market is estimated to be worth billions of dollars annually. The current TAM is projected at approximately $20-30 Billion. QuantumSi is positioned to capture a share of this market with its novel protein sequencing platform, though its market penetration is still very nascent.
Upturn SWOT Analysis
Strengths
- Novel technology platform
- Potential for high sensitivity
- Experienced leadership team
- Strong intellectual property portfolio
Weaknesses
- Limited commercial traction
- High operating expenses
- Dependence on key personnel
- Requires more validation of technology to establish long-term reliability
Opportunities
- Growing proteomics market
- Partnerships with pharmaceutical companies
- Expansion into new applications
- Potential for improved drug discovery
Threats
- Competition from established players
- Technological obsolescence
- Regulatory hurdles
- Economic downturns
Competitors and Market Share
Key Competitors
- PACB
- ILMN
- SOMA
Competitive Landscape
QuantumSi's advantage lies in its single-molecule protein sequencing technology. The disadvantage is the lack of validation and low market traction compared to established players.
Growth Trajectory and Initiatives
Historical Growth: Historical growth has been focused on product development and validation. Commercial growth is still in its early stages.
Future Projections: Analyst estimates vary widely. Look for consensus estimates on revenue growth and profitability. A large part of the company's near-term success depends on the market adoption of its Platinum system.
Recent Initiatives: Recent initiatives include new product launches, partnerships, and collaborations. These initiatives are aimed at expanding the companyu2019s reach and accelerating growth.
Summary
QuantumSi is a high-risk, high-reward company. Their single-molecule protein sequencing platform has the potential to disrupt the proteomics market. However, it faces challenges from established players and needs to demonstrate commercial viability and platform reliability. The company's long-term success depends on the market adoption of its technology and it should look out for cash constraints.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q)
- Company Investor Relations Website
- Third-Party Financial Data Providers
- Analyst Reports
- Press Releases
Disclaimers:
This analysis is for informational purposes only and does not constitute financial advice. Market share data are estimated and may not be precise. Investment decisions should be based on thorough research and consultation with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About QuantumSi Inc
Exchange NASDAQ | Headquaters Branford, CT, United States | ||
IPO Launch date 2021-06-10 | President, CEO & Director Mr. Jeffrey Alan Hawkins | ||
Sector Healthcare | Industry Medical Devices | Full time employees 149 | Website https://www.quantum-si.com |
Full time employees 149 | Website https://www.quantum-si.com | ||
Quantum-Si incorporated, a life sciences company, engages in the development of single-molecule detection platform to enable Next Generation Protein Sequencing (NGPS). The company offers Platinum NGPS instrument that provides single molecule amino acid level resolution with a streamlined workflow, including automated data analysis that accessible to researchers in all laboratory types; Platinum Pro NGPS instrument, a single molecule amino acid resolution, which provides an enhanced user interface, cloud or on instrument data analysis and an available pro mode; Library preparation kits to prepare protein sample for sequencing; Barcoding Kits to optimize the workflow and performance of technology; and Sequencing Kits contains the reagents and consumables used to perform NGPS on the Platinum or Platinum Pro instrument. It also provides Platinum Analysis Software, a cloud-based solution that automates data analysis workflows and provides a user-friendly interface and visualization of the sequencing results. Its products are used in antibody characterization, biomarker identification, protein identification, protein variants, protein barcoding, and post translational modification analysis applications. Quantum-Si incorporated was founded in 2013 is headquartered in Branford, Connecticut.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.